灵芝补肺散结方治疗中晚期非小细胞肺癌23例临床观察  

Clinical effect of Lingzhi Bufei Sanjie prescription in treatment of advanced non-small cell lung cancer: An analysis of 23 cases

作　　者：许洁 黄立中[1] XU Jie;HUANG Lizhong(Hunan University of Chinese Medicine,Changsha 410208,Hunan,China)

机构地区：[1]湖南中医药大学,湖南长沙410208

出　　处：《湖南中医杂志》2020年第6期12-14,34,共4页Hunan Journal of Traditional Chinese Medicine

摘　　要：目的:观察灵芝补肺散结方治疗中晚期气阴两虚型非小细胞肺癌(NSCLC)的临床疗效。方法:选择中晚期气阴两虚型NSCLC患者46例,随机分为治疗组和对照组,每组各23例。对照组采用GP方案化疗,治疗组在对照组的基础上加用自拟灵芝补肺散结方治疗,比较2组的近期疗效、生存质量(KPS)评分、中医证候(咳嗽、痰血、胸闷气促、神疲乏力)积分以及生存情况。结果:近期疗效总有效率治疗组为60.87%(14/23),对照组为26.08%(6/23),2组比较,差异有统计学意义(P<0.05);2组KPS评分、中医证候积分治疗前后组内比较及治疗后组间比较,差异均有统计学意义(P<0.05);治疗组中位无进展时间8.5个月,中位生存时间12.4个月,对照组分别为5.9个月和8.3个月,2组比较,差异有统计学意义(P<0.05)。结论:灵芝补肺散结方联合化疗治疗中晚期气阴两虚型NSCLC,能提高患者生存质量,改善其临床症状,延长中位生存期及疾病无进展生存期,疗效优于单纯化疗,值得临床借鉴。Objective:To investigate the clinical effect of Lingzhi Bufei Sanjie prescription in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:A total of 46 patients with advanced NSCLC with deficiency of both Qi and Yin were randomly divided into treatment group and control group,with 23 patients in each group.The patients in the control group were given chemotherapy with gemcitabine and paclitaxel,and those in the treatment group were given self-made Lingzhi Bufei Sanjie prescription in addition to the treatment in the control group.The two groups were compared in terms of short-term response,Karnofsky Performance Scale(KPS)score,scores of traditional Chinese medicine(TCM)syndromes(cough,bloody phlegm,chest distress and shortness of breath,and fatigue and weakness),and survival.Results:There was a significant difference in short-term overall response rate between the treatment group and the control group[60.87%(14/23)vs 26.08%(6/23),P<0.05].Both groups had significant changes in KPS score and TCM syndrome scores after treatment,and there were significant differences in these scores between the two groups after treatment(P<0.05).There were significant differences between the treatment group and the control group in median progression-free survival time(8.5 months vs 5.9 months,P<0.05)and median survival time(12.4 months vs 8.3 months,P<0.05).Conclusion:In the treatment of advanced NSCLC with deficiency of both Qi and Yin,Lingzhi Bufei Sanjie prescription combined with chemotherapy can improve patients’quality of life and clinical symptoms and prolong median survival time and progression-free survival,with a better clinical effect than chemotherapy alone,and therefore,it holds promise for clinical application.

关 键 词：中晚期非小细胞肺癌 气阴两虚证 灵芝补肺散结方 化疗 

分 类 号：R273.42[医药卫生—中西医结合]